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Abstract 
Study Objective: The free fraction of valproate (the pharmacologically active moiety, normally 5-
10%) may vary significantly in critically ill patients, but this topic is understudied, with only 4 prior 
ICU case reports. The objective of this study was to evaluate the range of valproate plasma protein 
binding in ICU patients.  
Design: Observational study of consecutive ICU patients 
Setting: Neurocritical and medical critical care services in a non-university academic medical center 
Patients: Consecutive ICU patients treated with valproate with serum albumin < 4 g/dL 
Measurements and Main Results: Simultaneous total and free trough serum valproate 
concentrations were measured as were serum creatinine, blood urea nitrogen BUN, albumin, 
platelets, and transaminase values. The reference concentration range was 50-125 mg/L (total) and 
5-17 mg/L (free). Valproate concentrations were categorized as within reference range, low, or high, 
and as concordant if both concentrations were in the same category. Data are reported as median 
(interquartile range).  Fifteen patients (9 males) were evaluated. The median age was 63 (34-70) 
years. The valproate dose was 3 g/day (35 mg/kg/day). No patient had a valproate free fraction of 5-
10%; the median was 48%, and the range was 15-89%. Total and free concentrations showed poor 
correlation (0.43) and were concordant in only 2 patients (both in reference range). Free valproate 
was poorly predicted by an equation correcting for albumin (r= 0.45). Suspected adverse drug events 
occurred in 10 patients: hyperammonemia in 7/12 tested (58%), elevated transaminases in 2/15 
(13%), and thrombocytopenia in 5/15 (33%). 
Conclusions: Protein binding of valproate is highly inconsistent in this cohort of ICU patients, and 
total valproate concentrations did not predict free concentrations, even when correcting for albumin. 
Additional research to define best practice for dosing and monitoring valproate and the relationship 
between free valproate concentrations and clinical or adverse effects in ICU patients is needed. 
I ntroduction 
 
Valproate is an antiepileptic and mood stabilizing agent approved by the Food and Drug 
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Administration in 1979.  Doses are typically adjusted to a total serum valproate concentration of 50-
100 mg/L when treating seizures and 50-125 mg/L for behavioral disorders.1,2  Valproate is highly 
protein bound to albumin (≥90%), and the pharmacologically active unbound or free fraction is 
typically 5-10% of the total valproate concentration, but may vary significantly.3  Valproate protein 
binding has been understudied, as we are aware of only 4 reported cases of free valproate 
monitoring in ICU patients.4-7  Reviews and guidelines recommend monitoring serum valproate 
concentrations, but make sparse or no mention of free serum concentration monitoring or altered 
protein binding.8-12
 
    
Our interest in monitoring free serum valproate concentrations began after treating a patient 
with decreasing total serum valproate concentrations despite increasing doses, with several adverse 
drug events. The free fraction and free serum valproate concentrations were elevated despite a low 
total concentration less than 30 mg/L. The primary objective of this study was to evaluate the 
frequency and extent of deranged valproate plasma protein binding in a cohort of consecutive 
critically ill patients. The secondary objectives were to assess the capability of a previously published 
equation to predict free serum valproate concentrations from albumin and total valproate 
concentrations.
 
13,14
 
Materials and Methods 
Index Case 
A 72-year-old man weighing 103 kg remained comatose after in-hospital cardiac arrest. Targeted 
temperature management was initiated at 33°C for 24  hours, with controlled rewarming over 12 
hours. On hospital day (HD) 3, he developed intermittent myoclonus with generalized polyspike and 
wave discharges of high amplitude on electroencephalography that persisted despite levetiracetam 
and continuous midazolam therapy. Because neuron-specific enolase testing and magnetic resonance 
imaging on HD4 did not identify severe brain injury, aggressive care was continued.  Valproate (30 
mg/kg/day) and a propofol infusion were added on HD4. On HD7, the total serum valproate 
concentration was 71 mg/L (reference range 50-100 mg/L), but a repeat total concentration on HD12 
was low (31 mg/L) despite no change in valproate dose (Figure 1). A 2000-mg dose of valproate was 
administered, and the maintenance dose increased to 40 mg/kg/day. On HD13, the total 
concentration was 30 mg/L, again prompting a valproate bolus and increase in the maintenance 
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regimen to 60 mg/kg/day. On HD14, the total concentration was lower at 26 mg/L, and the dose 
increased again to 80 mg/kg/day.  Serum for total and free valproate concentration measurement 
was sent to a reference lab, which returned on HD16, revealing an even lower total concentration [22 
mg/L), an elevated free concentration of 19 mg/L (reference range 5-17 mg/L), and a dramatically 
elevated free fraction of 86%. Coupled with an elevated ammonia concentration (135 μmol/L) and 
worsening transaminases, valproate therapy was discontinued. After repeated failures to control 
epileptiform discharges, the family requested withdrawal of life-sustaining therapy. 
Study Design 
Maine Medical Center (MMC) is an academic medical center with 58 adult ICU beds.  We 
prospectively monitored consecutive adult patients admitted to the neurocritical or medical critical 
care services from September 2015 through August 2016 who were treated with valproate with 
serum albumin concentrations < 4.0 g/dL. When the bedside treatment team ordered valproate 
concentrations, simultaneous total and free serum valproate concentrations were obtained. Total and 
free valproate assays were sent to a reference lab [Mayo Clinic Medical Laboratories, Rochester, MN) 
with a delay of several days. Total serum valproate and free serum valproate concentrations were 
determined via enzyme immunoassay using the Roche Cobas 8000 system. Free serum valproate was 
measured after ultrafiltration with the Millipore Centrifree micropartition system (EMD Millipore, 
Billerica, MA). In response to the index case, this study was designed as a Quality Improvement pilot 
project with approval by our IRB. 
 
 We collected patient demographic data including age, gender, weight, reason for ICU 
admission, length of stay, serum albumin, blood urea nitrogen, and creatinine concentration on the 
day simultaneous free and total serum concentrations were measured. I f more than one free 
valproate concentration was obtained, the sample with the highest free fraction was used. 
 
 Drug administration data were collected from the electronic Medication Administration Record, 
including the dose (g/day and mg/kg/day) on the day the serum concentrations were obtained, 
indication for valproate therapy, whether valproate was started during this ICU admission, and time 
from valproate initiation to measurement of serum concentrations. Concomitant administration of 
aspirin, propofol, and/or Intralipid®  was recorded. Inappropriate dose escalation was defined as an 
increase in valproate dose based on total serum valproate concentration, when the free concentration 
Au
th
or
 M
an
us
cr
ip
t
5 
 
This article is protected by copyright. All rights reserved 
suggested the dose should not have been increased. 
 
Outcomes and Statistical Analysis 
 We assessed possible valproate-induced adverse effects during valproate administration until 
hospital discharge. Only patients who had baseline laboratory values prior to valproate initiation were 
assessed for laboratory-based adverse effects. Hepatotoxicity was defined as a new alanine 
aminotransferase (ALT) > 3 times the upper limit of normal (ULN) (> 120 U/L), alkaline phosphatase 
> 2 times the ULN (> 234 U/L), total bilirubin > 2 times the ULN (> 2 mg/dL), or a doubling of the 
baseline value for ALT, alkaline phosphatase, or bilirubin if abnormal prior to valproate initiation.15  
Thrombocytopenia was defined as a platelet count < 140,000 cells/mm3 or reduction in platelet count 
by > 50% if platelets were already < 140,000 cells/mm3 following valproate initiation.16 
 
 
Hyperammonemia was defined as a new serum ammonia level ≥60 umol/L following valproate 
initiation. 
We compared the measured free serum valproate concentration to a predicted free serum 
concentration derived from the equation published by Parent et al: free fraction (%) =  Ae-BX, where X 
corresponds to albumin concentration (mmol/L), with constants A =  130.69 and B =  4.96 x 10-3.13,14 
The total, free, and predicted free serum valproate concentrations were compared using the 
Spearman correlation, and the bias between mean differences was assessed with Altman-Bland 
analysis by Analyse-it®  software.17
Results 
  Concentrations were categorized relative to the reference ranges 
for total (50-125 mg/L) and free (5-17 mg/L) serum valproate concentration as in the reference 
range or below (“low”) or above the reference range (“high”). I f both total and free concentrations 
were in the same category, we considered them therapeutically concordant.  I f the concentrations 
were in different categories, they were considered therapeutically discordant.  Data are presented as 
median (interquartile range or IQR) with p< 0.05 considered significant. 
 
From September 2015 through August 2016, 15 medical or neurological critical care patients 
were monitored (including the Index Case). The subjects were mostly male with a wide distribution 
of ages (Table 1).  Valproate was administered for seizures (n= 6), myoclonus (n= 4), bipolar disorder 
(n= 3), schizophrenia (n= 1), or refractory agitated behavior (n= 1). Three patients (20%) were 
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receiving valproate at the time of ICU admission at the same dose used prior to hospitalization 
The total serum valproate concentration was 52 mg/L (IQR, 29-65 mg/L) with a range of 22-
92 mg/L, representing low or reference range values only.  No patient had a valproate free fraction of 
5-10%; the median unbound or free valproate fraction was 48% (IQR, 39-56%; range, 15-89%).  
Despite the low or reference range total valproate levels, the increased free fraction was associated 
with free serum valproate concentrations that were often above the reference range at 20 (IQR 18-
30) mg/L (range, 11-37 mg/L).  The median valproate dose was 3.0 g/day (IQR, 2.0–4.0 g/day) or 
35 mg/kg/day (IQR, 27-43 mg/kg/day).  On the day valproate concentrations were drawn (drug day 
4 [ IQR 3-11] , the median albumin value was 2.4 g/dL (IQR, 2.2-3.0 g/dL), blood urea nitrogen was 
21 mg/dL (IQR, 15-28 mg/dL) mg/dL, and serum creatinine was 0.87 mg/dL (IQR, 0.56-1.2 mg/dL). 
Eight patients (53%) were receiving medications known to alter valproate protein binding; propofol 
infusions (n= 5), aspirin (n= 2), and both propofol and aspirin (n= 1) (Table 2). The median time from 
drawing the serum sample to valproate concentration  availability was 3 days (range, 2-4 days). 
 
The total serum valproate concentration was low in 6 (40%) patients, and in reference range 
in 9 (60%) patients (Figure 2).  The free valproate concentration was never low, but was high in 12 
(80%) patients and in reference range in 3 (20%) patients.  Total and free concentrations were 
concordant in only 2 patients (13%). Among the 6 patients with low total concentrations, which 
would likely have resulted in valproate dose increases based on the total concentration, free 
concentrations were high in 5 (83%).  
 
The correlation was poor between total and free serum valproate concentration (r= 0.43), 
between measured and predicted free serum valproate concentration (r= 0.45) (Figure 3), and 
between albumin and free fraction (r= 0.21). When the bias between measured and estimated free 
serum valproate concentrations using the Parent formula was compared using Altman-Bland 
techniques (eFigure 1), the Parent formula consistently underestimated free concentrations with a 
bias of -11.9 mg/L, and 95% Limits of Agreement of -28 to 4.2.  
 
Adverse drug events possibly associated with valproate therapy occurred in 10 patients (68%) 
(Figure 2). Seven of 12 patients tested (58%) had hyperammonemia, 2/15 (13%) developed 
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elevated transaminases, and 5/15 (33%) had thrombocytopenia.  Unexpectedly, four of the five 
patients without adverse drug events had among the highest free concentrations we recorded. The 
first 2 patients monitored received inappropriate dose adjustments based on total serum valproate 
concentrations. Learning from those events, providers checked free serum valproate concentrations 
earlier, and none of the next 13 patients received dose supplements inappropriately.   
 
Discussion 
No patient in our consecutive series had a normal free fraction of valproate of 5-10%, instead 
concentrations ranged from 15-89%.  Monitoring total concentrations of medications is based on the 
assumption that they reflect free concentrations (i.e. that the free fraction is predictable and is 
consistent between patients);18 clearly this is not the case for valproate among our cohort of ICU 
patients. Total serum valproate concentrations were usually low or in the reference range, yet the 
free concentration was usually above the reference range.  The free fraction was extremely variable, 
making any estimate based on the total concentration highly inaccurate. Even using a published 
formula to predict the free fraction and free concentration showed poor agreement with the actual 
measured values, perhaps because this formula was derived from non-ICU patients.13
 
  The 
complexity of valproate protein binding among critically ill patients this issue suggests that monitoring 
actual free valproate concentrations may be necessary in ICU patients.  
Our study represents the largest reported cohort of ICU patients with measured free serum 
valproate concentrations.  Our data highlight the potential benefit of monitoring free serum valproate 
concentrations in critically ill patients, and increase the reported cases in the ICU literature nearly 
five-fold. This is important because valproate is a preferred agent for seizure control and is an 
emerging option for the management of ICU agitation.8-10,19  A recent report suggests that valproate 
may be more effective (75%) than phenytoin (59%) or levetiracetam (52%) to control status 
epilepticus.20  With recent recommendations to aggressively treat post-cardiac arrest patients with 
seizures and myoclonus, it is likely that valproate use will increase in this patient population.
 
21
 
Several clinical factors common in the ICU are associated with higher free fractions of 
valproate, including uremia, hypoalbuminemia, free fatty acid administration (eg, Intralipid® , 
propofol, or clevidipine), and drug-drug interactions resulting in competition for albumin binding sites 
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(eg, aspirin and ibuprofen).18,22  Though documented more than 30 years ago, the potential utility of 
monitoring free serum valproate concentrations is not mentioned in recent clinical reviews or 
guidelines,8-10,23 and few ICU reports have been published.4-7  More than 10 years ago, a formula to 
adjust total valproate concentrations was proposed because only 2% of labs were measuring free 
concentrations,24
Older studies of outpatients treated with valproate concluded that monitoring free serum 
valproate concentrations was rarely helpful in patients without liver or renal disease or low albumin 
levels, showing free fractions in the expected range of 4-11%.
 but our data suggest this formula is unreliable in ICU patients.  
25,26
 They also showed no better 
relationship between seizure control or adverse effects with free versus total concentration 
monitoring for these patients. 25,26 These data may have misled clinicians who work with critically ill 
patients at risk for altered protein binding. Elevated free serum valproate concentrations have been 
associated with ataxia, nystagmus, unsteady gait, and vomiting,27 may be a stronger predictor of 
hyperammonemia than valproate dose or total concentration,28 and may be inversely related to 
platelet count.
 
29
 
Valproate exhibits concentration-dependent protein binding,1 and in addition to the above 
factors known to alter protein binding, the normal free fraction of 5-10% may increase to 30% or 
higher when total concentrations exceed 72 mg/L.23 Only one of our 15 patients had a serum total 
concentration greater than 72 mg/L.  As a low extraction ratio drug, valproate clearance is dependent 
on intrinsic hepatic clearance and free fraction; as free fraction increases, drug metabolism increases, 
potentially leading to lower than expected total serum concentrations, yet appropriate or even 
elevated free concentrations.4,11 This phenomenon may be even more pronounced in patients 
undergoing targeted temperature management because intrinsic hepatic clearance may be 
reduced.
 
30,31
 
Hypoalbuminemia is a common risk factor for an increased free fraction of valproate.4,6,32,33  
The largest study published to date (including both hospitalized and outpatients) concluded that 
albumin values < 3.5 g/L were associated with increased valproate free fractions, the only factor 
explaining therapeutic discordance between free and total serum valproate concentrations.33  All 
patients in our study had albumin concentrations less than 3.7 g/dL. Uremia may also alter valproate 
protein binding, with free fractions of 20% with renal dysfunction compared to 8% without, and a 
Au
th
or
 M
an
us
cr
ip
t
9 
 
This article is protected by copyright. All rights reserved 
moderate correlation has been observed between valproate free fraction and both serum creatinine 
and blood urea nitrogen.34
 
  
Free fatty acids can displace highly protein bound drugs due to their high binding affinity. 
Stearic, palmitic, oleic, and linoleic acid have been shown to increase the free fraction of valproate in 
a concentration-dependent fashion by 19-118%.35 Propofol and Intralipid®  are rich in free fatty 
acids, and have been shown to increase the free fraction of valproate.36 Six of our patients were 
receiving propofol infusions. Although no patient in our study was receiving clevidipine, this  
dihydropyridine calcium channel blocker also contains free fatty acids and would likely increase the 
free fraction of valproate. Antipyretic doses of aspirin may result in a fourfold increase in valproate 
free fraction, and similar effects have been seen with lower salicylate doses (325 mg/day).22,37 
Ibuprofen can also displace valproate leading to decreasing total serum concentrations and the risk 
for inappropriate dose increases.
 
38,39
 
Several limitations of our case series warrant comment. These data are from a single hospital, 
but the types of patients reported and medications co-administered are not unique to our center. We 
collected data from a consecutive series of patients over one year, but unexpected biases are 
possible. Two different total valproate reference ranges are accepted: 50-100 mg/L for seizure 
management and 50-125 mg/L for behavioral issues.  We selected the more inclusive 50-125 mg/L 
because some patients received valproate for behavioral issues. Though the range of 50-125 mg/L 
may have biased our sample toward more discordance, no patient had a total concentration > 100 
mg/L. 
 
The data supporting specific clinical effects and adverse events associated with discrete free 
serum valproate concentrations are not robust, which may be the greatest limitation of our report. 
Indeed, 80% of the five patients without adverse events had higher values for free and total 
valproate concentrations. Many different reference ranges for free serum valproate concentrations 
have been published (eTable 1).5,6,7,26,32,40-42 The median and interquartile range from these reports 
identifies a low reference value of 5 mg/L (IQR, 4.95-5 mg/L) and a high value of 12.9 mg/L (IQR, 
10-15.7 mg/L) similar to our reference range.  Even if we used the highest reported range for free 
valproate concentrations as reported in the literature (6-20 mg/L), seven of our patients were above 
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this threshold, and all were discordant (two low total concentrations, and five within the reference 
range of 50-100 mg/L). 
 
Conclusions 
 
These cases highlight the great variability of valproate protein binding and free fraction among 
ICU patients and the potential problems associated with adjusting valproate doses based on total 
serum valproate concentrations. Estimating free valproate fraction or concentration by correcting for 
albumin level was similarly inaccurate in our ICU cohort.  Monitoring free serum valproate 
concentrations may be appropriate for ICU patients with hypoalbuminemia, uremia, substances 
known to displace valproate from albumin (e.g., aspirin, ibuprofen, Intralipid® , propofol, or 
clevidipine), total concentrations in the high-end of the reference range (> 72 mg/L), or unexpectedly 
low total serum valproate concentrations. Additional research to define best practice for dosing and 
monitoring valproate and to determine the relationship between free serum valproate concentrations 
and clinical and adverse effects in ICU patients is needed. 
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Tables 
 
Table 1: Patient demographics and clinical outcomes 
Demographics 
Age, years 63 (29-72) 
Male, N (%) 9 (60%) 
Ethnicity, Caucasian 14 (93%) 
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ICU admitting diagnosis  
Cardiac Arrest 5 (33%) 
Seizures 4 (27%) 
Acute respiratory failure 4 (27%) 
Sepsis 1 (7%) 
HSV encephalitis 1 (7%) 
Weight, kg median (IQR) 95 (73-109) 
Outcomes 
ICU mortality 3 (20%) 
Hospital mortality 6 (40%) 
Discharge disposition  
Deceased 6 (40%) 
Rehabilitation 4 (27%) 
Home 3 (20%) 
Transfer 2 (13%) 
ICU length of stay, days median (IQR) 11 (8-27) 
Hospital length of stay, days  21 (10-34) 
Continuous variables reported as median (IQR), nominal variables as frequency n (%) 
 
 
 
 
 
 
Table 2:  Our 15 ICU cases of free valproate monitoring and 4 previously reported cases 
 
Case Age 
years 
Gender Dose 
grams 
Albumin  
g/dL 
BUN 
mg/dL 
Creat 
mg/dL 
Drugs Total 
Valproate 
mg/L 
Free 
Valproate 
mg/L 
Free 
Fraction 
Adverse 
Events 
1 72 M 6 2.2 27 0.87 PS 22.2 19 0.86 A, H, D 
2 62 M 4 2 49 1.14 - 53 20 0.38 A,D 
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3 93 F 3 2.4 27 1.06 P 71 37 0.52 - 
4 69 M 2 2.7 8 0.56 - 53 32 0.6 - 
5 19 F 4 3 9 0.32 - 42 18 0.43 A 
6 72 F 1 2.1 57 3.3 S 52.1 18 0.35 A,T 
7 26 M 3 2.4 18 0.57 P 29.1 26 0.89 A,T 
8 69 M 3 2.4 33 1.21 - 65 31 0.48 - 
9 67 F 2 3.2 26 5.6 - 23 19 0.83 - 
10 81 M 2.25 2.2 8 0.57 P 73 11 0.15 T 
11 51 F 3.6 2.7 12 0.41 - 47 22 0.47 A 
12 24 M 4 2.9 29 4.3 P 27 13 0.48 H,T 
13 29 F 1 3.7 19 0.95 - 51 12 0.24 A 
14 63 M 4.5 3 19 0.49 S 56 29 0.52 - 
15 40 M 3 2.2 21 0.57 P 92 37 0.4 T 
Median 
(IQR) or 
N(%) 
63 (34-
70) 
9 M 
(60%) 
3 (2-4) 2.4 (2.2-
3.0) 
21 
(15-
28) 
0.87 
(0.56-
1.2) 
6 P 
(40%)  
3 S 
(20%) 
52 (29-65) 20 (18-30) 0.48 
(0.39-
0.56) 
7A, 2 H, 5 
T, 2 D 
Ref 4 52 F 3.5 1.6 * * * 46 35 0.76 T,D 
Ref 5 29 * * 0.8 * * - 14 13 0.93 D 
Ref 6 61 F 0.9 1.2 * * - 15.5 9.3 0.60 D 
Ref 7 53 M 2.4 2.1 * * * 62 17 0.27 A 
 
Data are presented as incidence (%) and median (interquartile range).  Drugs =  medications that 
alter valproate protein binding - P =  Propofol, S= Salicylate; M =  Male, F =  Female; A =  Ammonia 
elevation, H =  hepatic dysfunction, T =  Thrombocytopenia, D =  Drug Dosing error, *  =  data not 
reported 
 
Figure Legends 
 
Fig 1 Index Case data showing decreasing total serum valproate concentrations (squares) despite 
repeated dose increases (vertical bars), and a free fraction on day 14 of 86% (free concentration 19 
mg/L - large triangle, total concentration 22 mg/L).   
 
 
Fig 2 Simultaneous free and total valproate concentrations.  The diagonal up to right shading reflects 
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the reference range for the free concentration on the Y axis (5-17 mg/L), the diagonal up to the left 
shading reflects the reference range for the total concentration on the X axis (50-125 mg/L), the solid 
grey rectangle reflects the concordance of the these two reference ranges. Triangles represent 
patients without adverse events. Diamonds represent patients with adverse events, two of which 
were therapeutically concordant (both in reference range with unfilled diamonds), the remaining 13 
symbols are solid diamonds or triangles reflecting therapeutically discordant values. 
 
 
Fig 3 Free versus estimated-free serum valproate concentration calculated from albumin using Parent 
formula. Diagonal line =  Line of Identity. The Parent formula underestimated free valproate 
concentrations (r =  0.45) 
 
 
Figure 1 
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